Denali Therapeutics (DNLI) Operating Income: 2017-2024
Historic Operating Income for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$129.8 million.
- Denali Therapeutics' Operating Income rose 2.06% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 147.76%. This contributed to the annual value of -$487.3 million for FY2024, which is 147.76% down from last year.
- Per Denali Therapeutics' latest filing, its Operating Income stood at -$129.8 million for Q4 2024, which was down 5.41% from -$123.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Operating Income ranged from a high of $244.1 million in Q4 2020 and a low of -$132.6 million during Q4 2023.
- In the last 3 years, Denali Therapeutics' Operating Income had a median value of -$115.2 million in 2023 and averaged -$85.4 million.
- In the last 5 years, Denali Therapeutics' Operating Income soared by 522.59% in 2020 and then crashed by 168.39% in 2024.
- Quarterly analysis of 5 years shows Denali Therapeutics' Operating Income stood at $244.1 million in 2020, then plummeted by 131.60% to -$77.1 million in 2021, then tumbled by 36.60% to -$105.3 million in 2022, then declined by 25.85% to -$132.6 million in 2023, then rose by 2.06% to -$129.8 million in 2024.
- Its last three reported values are -$129.8 million in Q4 2024, -$123.2 million for Q3 2024, and -$116.6 million during Q2 2024.